BridgeBio Pharma Inc

BBIO: XNAS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
<yLLOCK|HzLOCK|lTq$&L>

BridgeBio's Impressive Phase 3 Infigratinib Data Adds Competitive Pressure to BioMarin's Voxzogo

Business Strategy and Outlook

BridgeBio Pharma is a biotechnology company focused on bridging the gap between genetic research and unmet patient needs. Its pipeline targets Mendelian disorders, precision oncology, and gene therapy, with four programs in late-stage development.

Sponsor Center